Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D5RH
|
|||
| Former ID |
DCL000651
|
|||
| Drug Name |
TAK-442
|
|||
| Synonyms |
Letaxaban; TAK-442; 870262-90-1; UNII-Y3WB03966W; TAK 442; CHEMBL1095032; Y3WB03966W; 1-(1-{(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone,1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-; Letaxaban [USAN:INN]; 1-[1-[(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl]piperidin-4-yl]tetrahydropyrimidin-2(1H)-one; 3kl6; Letaxaban (USAN/INN); SCHEMBL766143; GEHAEMCVKDPMKO-HXUWFJFHSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Discontinued in Phase 2 | [1] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H26ClN3O5S
|
|||
| Canonical SMILES |
C1CNC(=O)N(C1)C2CCN(CC2)C(=O)C(CS(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl)O
|
|||
| InChI |
1S/C22H26ClN3O5S/c23-17-4-2-16-13-19(5-3-15(16)12-17)32(30,31)14-20(27)21(28)25-10-6-18(7-11-25)26-9-1-8-24-22(26)29/h2-5,12-13,18,20,27H,1,6-11,14H2,(H,24,29)/t20-/m1/s1
|
|||
| InChIKey |
GEHAEMCVKDPMKO-HXUWFJFHSA-N
|
|||
| CAS Number |
CAS 870262-90-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor Xa (F10) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027537) | |||
| REF 2 | Clinical pipeline report, company report or official report of Takeda (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.